Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This Review reviews changes introduced into the US brain death/death by neurological criteria (BD/DNC) guidelines in 2023 and compares these guidelines with those formulated elsewhere in the world. The authors highlight controversies and legal challenges in BD/DNC determination and discuss future research priorities.
A study now reveals that CSF, but not imaging, biomarkers for Alzheimer disease show weaker correlation to cognitive measures in Black people than in White people. The findings offer insights into Alzheimer disease biomarker utility across racially diverse groups.
Though the burden of stroke has declined, it has grown rapidly in low-income and middle-income countries, and disparities still exist within high-income countries. In this Review, the authors highlight under-acknowledged disparities in the burden of stroke and review strategies for addressing key inequalities.
In this Perspective, the authors discuss the need for neurologists to assist in court cases involving criminal behaviour that was potentially influenced by a neurological disorder. The authors review evidence linking neurological disorders with criminal activity, and advocate for the development of forensic neurology as a subspecialty of the field.
Parkinson disease psychosis comprises a spectrum of illusions, hallucinations and delusions that emerge during the disease course. This Review considers clinical, neuroimaging and neurochemical evidence that might aid early identification of psychotic phenomena in people with Parkinson disease and inform new therapeutic strategies.
Autonomic nervous system dysregulation contributes to the chronic, debilitating disorders referred to as ‘long COVID’ or post-acute sequelae of SARS-CoV-2 infection (PASC). Here, Goldstein describes a multisystem, multidisciplinary approach to understanding PASC-induced alterations in feedback-regulated, plastic networks that determine homeostasis and allostasis.
Increasing evidence suggests that inflammasome activation contributes to disease progression in a wide variety of neurological conditions. In this Review, Ravichandran and Heneka discuss current understanding of inflammasome activation in neurological disorders and consider interventional strategies that target inflammasome activation.
This Review provides a comprehensive summary of the growing number of molecular therapies for the treatment of myasthenia gravis, including monoclonal antibodies, B cell-depleting agents and chimeric antigen receptor T cell-based therapies.
In this Perspective, Zech and Winkelmann outline multidimensional strategies for genetic diagnosis in patients with rare movement disorders and highlight community-driven data-sharing and case-matchmaking platforms designed to foster the discovery of new genotype–phenotype relationships.
Glyphosate, a controversial herbicide, has been approved for use in the European Union for another 10 years despite uncertainty over whether it increases the risk of neurodegenerative disorders such as Parkinson disease. We call for new approaches to assessing the neurotoxicity of glyphosate and other pesticides and improving their regulation.